Fig. 1 · Structure

Documents & Downloads

Bay 11-7821

Cat. No. A11957 CAS 19542-67-7

IκB/IKK inhibitor

Bay 11-7821 is an irreversible inhibitor of TNF-α-stimulated IκBα phosphorylation.

In Stock

Publications for Bay 11-7821

4 publications citing this product

  1. Majid Momeny, .et al. , EMBO Mol Med, 2024, Jun 17 PMID: 38886591
  2. Ali Nasrollahzadeh, .et al. , Rep Biochem Mol Biol, 2022, Jan;10(4):602-613 PMID: 35291620
  3. Ali Nasrollahzadeh, .et al. , Life Sci, 2020, Jul 6;257:118060 PMID: 32645343
  4. Momeny M, .et al. , Int J Biochem Cell Biol, 2018, Jun;99:1-9 PMID: 29567488

Free Aliquoting for Your Order

Tell us your preferred amount per vial. We’ll confirm the options.

Biological Activity

Bioactivity / Mechanism

BAY 11-7082, a catalog synonym of Bay 11-7821, suppresses IL-1-induced canonical NF-κB pathway signaling in cells. In a cell-free assay it also inhibits ubiquitin loading onto the E2 enzymes Ubc13 and UbcH7 while sparing UBE1 loading under the tested conditions. These findings limit interpretation of BAY 11-7082 as a selective pathway probe. [1]

Literature-reported observations and conditions; not Adooq-tested protocols or general treatment recommendations.

Target & Activity

Target Activity Value
E2-conjugating enzymes (Cell-free assay) N/A
IκBα?phosphorylation (Tumor cells) 10 μM

Cellular Effect

Cell Line Activity Value Description Reference
HEK293 IC50 11 μM Inhibition of TNFalpha-induced NFkappaB activation in human HEK293 cells after 6 hrs by luciferase assay [PMID: 32163285]
HEK293 IC50 2 μM Inhibition of TNFalpha-induced NF-kappaB activity (unknown origin) transfected in HEK293 cells after 6 hrs by luciferase reporter gene assay [PMID: 26343828]
HEK293 IC50 2 μM Inhibition of TNF-alpha-induced NF-kappaB activity in HEK293 cells after 6 hrs by luciferase reporter gene assay [PMID: 24992702]
HEK293 IC50 2 μM Inhibition of TNF-alpha-induced NF-kappaB activity in HEK293 cells after 6 hrs by luciferase reporter gene assay [PMID: 24533857]
HEK293 IC50 2 μM Inhibition of TNFalpha-induced NF-kappaB activity expressed in human HEK 293 cells after 6 hrs by luciferase reporter gene assay [PMID: 22850207]
HEK293 IC50 2.01 μM Inhibition of TNFalpha-induced human NFkappaB activity in HEK293 cells incubated for 6 hrs followed by compound wash out measured after 5 mins by by luciferase assay [PMID: 22712432]
HEK293 IC50 5 μM Inhibition of TNFalpha-induced NFkappaB (unknown origin) activation expressed in HEK293 cells after 6 hrs by luciferase reporter gene assay [PMID: 23316950]
RAW264.7 IC50 1.72 μM Inhibition of LPS-induced NF-kappaB activation in mouse RAW264.7 cells treated 30 mins before LPS challenge measured after 6 hrs by luciferase reporter gene assay [PMID: 24315191]
RAW264.7 IC50 5180 nM Inhibition of LPS stimulated TNF-alpha production in mouse RAW264.7 macrophages preincubated for 1 hr followed by LPS stimulation and measured after 24 hrs by EIA [PMID: 33601311]
SH-SY5Y IC50 0.85 μM Anticancer activity against human SH-SY5Y cells assessed as reduction in cell viability incubated for 48 hrs by resazurin dye based fluorescence assay [PMID: 36208544]
SK-N-AS IC50 1.23 μM Anticancer activity against human SK-N-AS cells assessed as reduction in cell viability incubated for 48 hrs by resazurin dye based fluorescence assay [PMID: 36208544]

11 records · Scroll to view more

Bay 11-7821 Research Summary

This section summarizes 3 in vitro studies and 1 in vivo study of Bay 11-7821 from 3 published references. In vitro models include reconstituted human UBE1 with Ubc13 or UbcH7 and ubiquitin; human IL-1 receptor-expressing HEK-293 cells. In vivo models include C57BL/6 mice challenged with synthetic poly U.

Bay 11-7821 In Vitro Studies

In a 24 h cancer-cell study, BAY 11-7082 enhanced the effect of arsenic trioxide on MTT viability in U87 and OVCAR-3 cells, but did not enhance it in PANC-1 cells. U87 combination analysis supported synergy; the reported combination index was 0.260 for 7.5 μM BAY 11-7082 plus 1 μM arsenic trioxide. The response was model-dependent and does not establish a selective NF-κB mechanism. [2]

Inhibition of ubiquitin loading onto E2 enzymes

Biochemical assay · Reconstituted human UBE1 with Ubc13 or UbcH7 and ubiquitin [1]

BAY 11-7082 blocked ubiquitin loading onto Ubc13 and UbcH7, while ubiquitin loading onto UBE1 remained detectable. Minus-MgATP and drug-free reactions provide assay controls. These gel endpoints are not IC50 measurements.

Measured endpoints — not treatment concentrations
EndpointReported resultReference
Ubc13–ubiquitin and UbcH7–ubiquitin conjugates versus UBE1–ubiquitin controlqualitative response E2 loading inhibited; UBE1 loading not inhibited under the tested conditions[1]

Literature-Reported Treatment Conditions

Treatment concentration
0.5, 1, 2, 4, 8 and 16 μM; 0 μM controls
Exposure duration
Figure 5 caption: 60 min preincubation. Shared E1/E2 assay method: 45 min at 21°C, then 10 min at 30°C after MgATP addition.
Method
Cell-free ubiquitin-loading assay; nonreducing SDS/PAGE and Coomassie staining
Vehicle
DMSO; matched DMSO control specified in the assay method
Reported limits
Preincubation duration differs between Figure 5 caption and shared methods (60 versus 45 min); unresolved. No IC50 or replicate n is provided in the selected caption.
Methods and source locations

Compound reported in the paper: BAY 11-7082; Compound label in the paper: Reported BAY 11-7082; catalog synonym of Bay 11-7821

Compound-level research applicability only; no salt conversion or validation of the current Adooq lot, purity or stereochemical composition.

Figure 5A–C and caption; Experimental Materials and E1/E2 ubiquitin-loading assays

Ubc13–ubiquitin and UbcH7–ubiquitin conjugates versus UBE1–ubiquitin control: SDS/PAGE, Coomassie stain — Figure 5A–C; Experimental: E1 and E2 ubiquitin-loading assays

Suppression of IL-1-induced canonical NF-κB pathway signaling

Cell-based study · Human IL-1 receptor-expressing HEK-293 cells [1]

BAY 11-7082 reduced IL-1β-induced IKKβ activation-loop phosphorylation and p105 phosphorylation and prevented IκBα degradation. The experiment measures cellular pathway activation, not direct inhibition of purified IKK.

Measured endpoints — not treatment concentrations
EndpointReported resultReference
Phospho-IKKβ, phospho-p105 and IκBα abundance relative to IL-1β-only and unstimulated controlsqualitative response IKKβ/p105 phosphorylation suppressed; IκBα degradation prevented[1]

Literature-Reported Treatment Conditions

Treatment concentration
0, 2, 5, 10 and 15 μM
Exposure duration
1 h pretreatment followed by 15 min IL-1β stimulation
Method
Immunoblotting after stimulation with 0.5 ng/ml IL-1β
Co-treatment
IL-1β is the assay stimulus, not a second therapeutic agent.
Reported limits
Vehicle concentration and biological replicate n are not specified in the selected activation-assay caption. Duplicate lanes are not assumed to be independent experiments.
Methods and source locations

Compound reported in the paper: BAY 11-7082; Compound label in the paper: Reported BAY 11-7082; catalog synonym of Bay 11-7821

Compound-level research applicability only; no salt conversion or validation of the current Adooq lot, purity or stereochemical composition.

Figure 2B and caption; Experimental Materials, cell stimulation/lysis and immunoblotting

Phospho-IKKβ, phospho-p105 and IκBα abundance relative to IL-1β-only and unstimulated controls: Immunoblotting; GAPDH loading control — Figure 2B and caption; Experimental: cell stimulation and immunoblotting

Cell-type-dependent interaction with arsenic trioxide

Cell-based study · U87 glioblastoma, OVCAR-3 ovarian carcinoma and PANC-1 pancreatic cancer cells [2]

Combination treatment lowered the MTT viability signal relative to arsenic trioxide alone in U87 and OVCAR-3 cells; no enhancement was reported in PANC-1 cells. U87 drug-interaction analysis supported synergy. MTT measures metabolic viability and does not itself establish apoptosis or a specific molecular target.

Measured endpoints — not treatment concentrations
EndpointReported resultReference
24 h MTT viability across the three cell modelsqualitative response ATO enhancement in U87 and OVCAR-3; no enhancement in PANC-1[2]
U87 interaction of 7.5 μM BAY 11-7082 with 1 μM arsenic trioxidecombination index (CI) 0.260[2]

Literature-Reported Treatment Conditions

Treatment concentration
BAY 11-7082 alone: 0, 2.5, 5, 7.5 and 10 μM. Combination: 7.5 or 10 μM BAY 11-7082 with 0–6 μM arsenic trioxide.
Exposure duration
24 h drug exposure
Method
MTT viability assay and U87 Chou–Talalay combination analysis
Vehicle
DMSO; final DMSO did not exceed 0.1% [v/v]. Statistical methods specify vehicle-treated controls.
Co-treatment
Arsenic trioxide, 0, 1, 2, 3, 4, 5 and 6 μM; single-agent series also tested.
Reported limits
Figure 1b displays each zero-ATO condition near 100%, whereas Figure 1a shows a BAY-only viability decrease; the normalization relationship is not explained in the inspected text. Absolute cross-panel effects and single-agent EC50 values are not extracted.
Methods and source locations

Compound reported in the paper: BAY 11-7082; Compound label in the paper: Reported BAY 11-7082; catalog synonym of Bay 11-7821

Compound-level research applicability only; no salt conversion or validation of the current Adooq lot, purity or stereochemical composition.

Materials and Methods: cell lines/drug treatment, viability, combination analysis, statistics; Figures 1–2; Table 2

24 h MTT viability across the three cell models: MTT; Figure 1 values reported as mean±SD of three independent experiments; methods describe triplicate evaluation — Figure 1a–b; first Results subsection; Statistical analysis

U87 interaction of 7.5 μM BAY 11-7082 with 1 μM arsenic trioxide: Chou–Talalay/CalcuSyn; CI < 1 defined as synergy. No uncertainty or row-specific n reported in Table 2. — Table 2, first data row; Drug combination analysis; Figure 2c

Bay 11-7821 In Vivo Studies

In C57BL/6 mice, intraperitoneal BAY 11-7082 pretreatment at 5 or 10 mg/kg reduced the serum IFN-α response to a synthetic poly U stimulus at 1, 3 and 6 h. This was an acute pharmacodynamic experiment with artificially induced IFN elevation, rather than evidence of efficacy in an SLE disease model. [3]

Attenuation of an induced serum IFN-α response

Animal study · C57BL/6 mice challenged with synthetic poly U [3]

BAY 11-7082 pretreatment reduced induced serum IFN-α at 1, 3 and 6 h compared with vehicle. The synthetic-stimulus experiment establishes acute pharmacodynamic activity; the authors explicitly note that IFN elevation was artificially induced and does not demonstrate prevention of SLE disease activity.

Measured endpoints — not treatment concentrations
EndpointReported resultReference
Serum IFN-α after synthetic poly U challengequalitative response Reduced at 1, 3 and 6 h versus challenged vehicle controls[3]

Conditions shared by the study groups

Route
Intraperitoneal
Frequency
One pretreatment described
Treatment course
1 h before synthetic poly U challenge; serum collected 1, 3 and 6 h after challenge
Vehicle
DMSO-dissolved BAY11; parallel vehicle control. Injection formulation and DMSO fraction not specified.
Study groups and reported outcomes
Group / doseComparatorObserved resultReference
BAY 11-7082 5 mg/kg
5 mg/kg bodyweight
Vehicle-pretreated, poly U-challenged miceLower serum IFN-α than vehicle-challenged controls at the measured time points.[3]
BAY 11-7082 10 mg/kg
10 mg/kg bodyweight
Vehicle-pretreated, poly U-challenged miceLower serum IFN-α than vehicle-challenged controls at the measured time points.[3]
BAY 11-7082 5 mg/kg
Model: C57BL/6 mice; sex and age not specified in the selected in-vivo methods
Reported limits: Sex, age, randomization and blinding not specified in the selected in-vivo methods/caption. Caption describes five independent experiments, except six hours n = 4; animals per experiment are not specified.
BAY 11-7082 10 mg/kg
Model: C57BL/6 mice; sex and age not specified in the selected in-vivo methods
Reported limits: Sex, age, randomization and blinding not specified in the selected in-vivo methods/caption. Caption describes five independent experiments, except six hours n = 4; animals per experiment are not specified.
Methods and source locations

Compound reported in the paper: BAY 11-7082; Compound label in the paper: Reported BAY 11-7082; catalog synonym of Bay 11-7821

Compound-level research applicability only; no salt conversion or validation of the current Adooq lot, purity or stereochemical composition.

Figure 7C and caption; Materials and methods: media/reagents, in-vivo assessment and cytokine ELISA; Discussion first paragraph

Serum IFN-α after synthetic poly U challenge: ELISA; Figure 7C bars are means of five independent experiments, except at six hours n = 4; Mann–Whitney test with *P < 0.05 and **P < 0.01 as displayed. — Figure 7C and caption; final Results subsection; Analyses of cells

BAY 11-7082 5 mg/kg · Figure 7C and caption; Materials and methods: in-vivo assessment and media/reagents

BAY 11-7082 10 mg/kg · Figure 7C and caption; Materials and methods: in-vivo assessment and media/reagents

Specifications

Manufacturer Adooq Bioscience
Actions Inhibitor
CAS Number 19542-67-7
Applications

IκB/IKK inhibitor

Formula C10H9NO2S
Molecular Weight 207.25
Synonyms Bay 11-7082
SMILES
CC1=CC=C(C=C1)S(=O)(=O)/C=C/C#N

Storage & Solubility

In Vitro Solubility

Reported Solubility

SolventReported Solubility
DMSO 39 mg/mL (188.17 mM)
Water Insoluble
Ethanol 10 mg/mL (48.25 mM)

Preparing Stock Solutions

Stock preparation is unavailable for this product molecular weight.

Calculated stock concentrations do not establish solvent solubility. Refer to the reported solubility data for experimental guidance.

In Vivo Preparation

Concentration
7 mg/mL
Vehicle
5% DMSO+corn oil

Storage

Store powder at -20°C, keep desiccated.
In powder form, the chemical is stable for 36 months.
In solution, store at -20°C and use within 1 month to prevent loss of potency. Aliquot to avoid multiple freeze/thaw cycles.

Bay 11-7821 Research References

  1. [1] Strickson S, Campbell DG, Emmerich CH, et al. The anti-inflammatory drug BAY 11-7082 suppresses the MyD88-dependent signalling network by targeting the ubiquitin system The Biochemical journal (2013). PMID: 23441730 DOI: 10.1042/bj20121651 Source material
  2. [2] Nasrollahzadeh A, Momeny M, Bashash D, et al. Blockade of Nuclear Factor-Κb (NF-Κb) Pathway Using Bay 11-7082 Enhances Arsenic Trioxide-Induced Antiproliferative Activity in U87 Glioblastoma Cells Reports of biochemistry & molecular biology (2022). PMID: 35291620 DOI: 10.52547/rbmb.10.4.602 Source material
  3. [3] Miyamoto R, Ito T, Nomura S, et al. Inhibitor of IkappaB kinase activity, BAY 11-7082, interferes with interferon regulatory factor 7 nuclear translocation and type I interferon production by plasmacytoid dendritic cells Arthritis research & therapy (2010). PMID: 20470398 DOI: 10.1186/ar3014 Source material

Publications

4 publications citing this product

  1. Majid Momeny, .et al. , EMBO Mol Med, 2024, Jun 17 PMID: 38886591
  2. Ali Nasrollahzadeh, .et al. , Rep Biochem Mol Biol, 2022, Jan;10(4):602-613 PMID: 35291620
  3. Ali Nasrollahzadeh, .et al. , Life Sci, 2020, Jul 6;257:118060 PMID: 32645343
  4. Momeny M, .et al. , Int J Biochem Cell Biol, 2018, Jun;99:1-9 PMID: 29567488

Added to your cart

View Cart Checkout
Loading...